29 completed, 9 recruiting, 4 not yet recruiting, 4 unknown. 18 Phase 2, 12 Phase 3, 9 Phase 4, 6 Phase 1, 1 Not applicable.
Follow Methotrexate (MTX): new trials by email Literature Review of Methotrexate (MTX) trials Research Report on Methotrexate (MTX)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004) MK-8690, Placebo, Methotrexate (MTX) - Rheumatoid Arthritis | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 60 | 2026-11-23 | 2026-11-16 |
| Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment Natrunix 400 mg, Placebo, Methotrexate (MTX) - Rheumatoid Arthritis | Phase 2 | Not yet recruiting | XBiotech, Inc. | 108 | 2026-07-15 | 2025-12-09 |
| Methotrexate for Severe Vulvar Lichen Sclerosus Methotrexate (MTX) - Vulvar Lichen Sclerosus | Phase 2 | Recruiting | Clinica Dermatologica Arbache ltda | 12 | 2026-01-21 | 2026-01-22 |
| A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE) PRX-115, Methotrexate (MTX), PRX-115 placebo - Gout | Phase 2 | Recruiting | Protalix | 150 | 2025-12-22 | 2026-09-29 |
| Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing Polychondritis Methotrexate (MTX), Azathioprine (AZA), Adalimumab - Relapsing Polychondritis | Phase 2 | Recruiting | University of Pennsylvania | 20 | 2025-11-11 | 2026-09-02 |
| The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial) Hydroxychloroquine (HCQ), Methotrexate (MTX) - Frontal Fibrosing Alopecia, Cicatricial Alopecia | Not yet recruiting | Erasmus Medical Center | 50 | 2025-11-01 | 2025-09-29 | |
| Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus Lenalidomide, Methotrexate (MTX) - Cutaneous Lupus Erythematosus (CLE) | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 122 | 2025-10-01 | 2025-05-11 |
| Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA Methotrexate (MTX), Placebo - Osteo Arthritis of the Knee, Synovitis of Knee | Phase 2 | Recruiting | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 70 | 2025-07-30 | 2025-09-12 |
| Changes in MTX-PG Concentrations During Subcutaneous MTX Therapy in Patients With Rheumatoid Arthritis(COSMOS Study) Methotrexate (MTX) - Rheumatoid Arthritis (RA) | Phase 4 | Recruiting | Keio University | 100 | 2025-04-10 | 2025-04-06 |
| A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux) - Graft-versus-host Disease (GVHD) | Phase 3 | Recruiting | Incyte Corporation | 572 | 2025-04-02 | 2026-10-22 |
| ZR-MTX for PIOL Phase II Trial Methotrexate, Rituximab (R), Zanubrutinib - Primary Intraocular Lymphoma | Phase 2 | Recruiting | Peking Union Medical College Hospital | 47 | 2024-10-10 | 2026-09-04 |
| MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial Methotrexate (MTX) - Polycythemia Vera (PV), Essential Thrombocythemia (ET) | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 54 | 2024-10-02 | 2025-12-17 |
| Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma Glucarpidase, Methotrexate (MTX) - Primary Central Nervous System Lymphoma | Phase 1 | Unknown | Assistance Publique - Hôpitaux de Paris | 18 | 2022-09-15 | 2022-10-25 |
| A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL Orelabrutinib, Rituximab, Methotrexate (MTX) - Primary Central Nervous System Lymphoma | Phase 1 | Completed | Huashan Hospital | 13 | 2021-10-10 | 2026-08-19 |
| Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy Pegloticase, Methotrexate (MTX) - Uncontrolled Gout | Phase 4 | Completed | Amgen | 11 | 2021-03-08 | 2024-06-27 |
| A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL) Pegloticase, Methotrexate (MTX) - Uncontrolled Gout, Chronic Gout | Phase 4 | Completed | Amgen | 54 | 2021-01-26 | 2026-05-19 |
| A Study to Evaluate the Safety and Tolerability of Multiple Doses of Gerilimzumab in Rheumatoid Arthritis Patients GB224 10mg, GB224 20mg - Rheumatoid Arthritis | Phase 1 | Unknown | Genor Biopharma Co., Ltd. | 24 | 2019-08-15 | 2019-11-27 |
| PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis ATG, CTX, Mycophenolate Mofetil - Hematopoietic Stem Cell Transplantation | Phase 4 | Unknown | Nanfang Hospital, Southern Medical University | 260 | 2018-10-29 | 2019-10-28 |
| Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout Pegloticase, Methotrexate (MTX), Standard Gout Flare Prophylaxis - Gout | Phase 4 | Completed | Amgen | 14 | 2018-09-26 | 2024-06-26 |
| Efficacy and Safety of Fecal Microbiota Transplantation in Peripheral Psoriatic Arthritis Fecal microbiota transplantation (FMT), Drug: Placebo (saline), Methotrexate (MTX) - Psoriatic Arthritis | Not applicable | Completed | Odense University Hospital | 31 | 2017-05-16 | 2020-12-07 |
Showing 20 of 48. Sign in to see all of them.
Arthritis, Rheumatoid (23) · Gout (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Arthritis, Psoriatic (3) · Graft vs Host Disease (3) · Arthritis (2) · Leukemia (2) · Lymphoma (2) · Alopecia (1) · Autoimmune Diseases (1) · Bronchiolitis Obliterans Syndrome (1) · Burkitt Lymphoma (1) · Hair Diseases (1) · Hodgkin Disease (1) · Hyperuricemia (1)
Amgen (3) · Pfizer (3) · Assistance Publique - Hôpitaux de Paris (2) · Centocor, Inc. (2) · Chelsea Therapeutics (2) · M.D. Anderson Cancer Center (2) · Merck Sharp & Dohme LLC (2) · AbbVie (1) · Antares Pharma Inc. (1) · Astellas Pharma Global Development, Inc. (1) · Astellas Pharma Inc (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Bristol-Myers Squibb (1) · Clinica Dermatologica Arbache ltda (1) · Eastern Cooperative Oncology Group (1)
United States (23) · China (5) · Spain (5) · Australia (4) · Canada (4) · Colombia (4) · Czechia (4) · Germany (4) · Italy (4) · Japan (4) · Mexico (4) · Poland (4) · Belgium (3) · United Kingdom (3) · Argentina (2)
Alan J Kivitz, MD;CPI (1) · Alice B. Gottlieb, M.D., PhD. (1) · Arthur A Kavanaugh, MD (1) · Claudio Anasetti, MD (1) · Edward Keystone, MD (1) · Francine M. Foss, MD (1) · James R O'Dell, MD (1)
PMID 18047523, PMID 21724705, PMID 21994233, PMID 22121129, PMID 22689677, PMID 23097311, PMID 24001888, PMID 24752047, PMID 24786931, PMID 25623393, PMID 25946554, PMID 26139005, PMID 27863807, PMID 28035867, PMID 28153828, PMID 28494788, PMID 29427176, PMID 29575803, PMID 29703851, PMID 31429794, PMID 32100960, PMID 32934137, PMID 33926922, PMID 34006020, PMID 35183373, PMID 35293984, PMID 35313978, PMID 36008814, PMID 36058784, PMID 36575505, PMID 38288922, PMID 38296309, PMID 39222436, PMID 40814761
2016 (2), 2008 (1), 2009 (1), 2015 (1), U10CA021115 (1)